Abstract
The Spike protein is the target of both antibody-based therapeutics (convalescent plasma, polyclonal serum, monoclonal antibodies) and vaccines. Mutations in Spike could affect efficacy of those treatments. Hence, monitoring of mutations is necessary to forecast and readapt the inventory of therapeutics. Different phylogenetic nomenclatures have been used for the currently circulating SARS-CoV-2 clades. The Spike protein has different hotspots of mutation and deletion, the most dangerous for immune escape being the ones within the receptor binding domain (RBD), such as K417N/T, N439K, L452R, Y453F, S477N, E484K, and N501Y. Convergent evolution has led to different combinations of mutations among different clades. In this review we focus on the main variants of concern, that is, the so-called UK (B.1.1.7), South African (B.1.351) and Brazilian (P.1) strains.
Keywords: B.1.1.7; B.1.351; BNT162b2; COVID-19; LY-CoV555; LyCoV016; P.1; P.2; REGN10933; REGN10987; SARS-CoV-2; bamlanivimab; casirivimab; convalescent plasma; etesevimab; imdevimab; immune escape; mRNA-1273; mutations; neutralising antibody; polyclonal immunoglobulins.
【저자키워드】 COVID-19, convalescent plasma, SARS-CoV-2, B.1.351, mRNA-1273, mutations, bamlanivimab, BNT162b2, Immune escape, Casirivimab, Imdevimab, B.1.1.7, P.1, etesevimab, neutralising antibody, P.2, REGN10933, REGN10987, LY-CoV555, LyCoV016, polyclonal immunoglobulins., 【초록키워드】 convalescent plasma, Efficacy, Mutation, Vaccines, spike, antibody, Therapeutics, B.1.351, immunoglobulins, variants of concern, monoclonal antibodies, immune, bamlanivimab, Spike protein, Receptor binding domain, BNT162b2, Protein, serum, Immune escape, Casirivimab, Imdevimab, L452R, B.1.1.7, RBD, Y453F, N501Y, mRNA, etesevimab, neutralising antibody, African, Deletion, clades, E484K, target, REGN10933, REGN10987, convergent evolution, convalescent, Strains, N439K, LY-CoV555, Combination, Phylogenetic, focus, South, circulating, S477N, hotspot, Affect, inventory, polyclonal, neutralising, 【제목키워드】 Vaccine, Risk assessment, SARS-CoV-2 spike,